Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies

Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within...

Descripción completa

Detalles Bibliográficos
Autores principales: Yetmar, Zachary A, Khodadadi, Ryan B, Seville, Maria Teresa, Brumble, Lisa, O’Horo, John C, Ganesh, Ravindra, Razonable, Raymund R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047222/
https://www.ncbi.nlm.nih.gov/pubmed/35791358
http://dx.doi.org/10.1093/ofid/ofac204
_version_ 1784695679966248960
author Yetmar, Zachary A
Khodadadi, Ryan B
Seville, Maria Teresa
Brumble, Lisa
O’Horo, John C
Ganesh, Ravindra
Razonable, Raymund R
author_facet Yetmar, Zachary A
Khodadadi, Ryan B
Seville, Maria Teresa
Brumble, Lisa
O’Horo, John C
Ganesh, Ravindra
Razonable, Raymund R
author_sort Yetmar, Zachary A
collection PubMed
description Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population.
format Online
Article
Text
id pubmed-9047222
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90472222022-04-28 Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies Yetmar, Zachary A Khodadadi, Ryan B Seville, Maria Teresa Brumble, Lisa O’Horo, John C Ganesh, Ravindra Razonable, Raymund R Open Forum Infect Dis Brief Report Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population. Oxford University Press 2022-04-14 /pmc/articles/PMC9047222/ /pubmed/35791358 http://dx.doi.org/10.1093/ofid/ofac204 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Yetmar, Zachary A
Khodadadi, Ryan B
Seville, Maria Teresa
Brumble, Lisa
O’Horo, John C
Ganesh, Ravindra
Razonable, Raymund R
Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
title Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
title_full Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
title_fullStr Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
title_full_unstemmed Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
title_short Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
title_sort outcomes of b-cell-depleted patients with coronavirus disease 2019 treated with antispike monoclonal antibodies
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047222/
https://www.ncbi.nlm.nih.gov/pubmed/35791358
http://dx.doi.org/10.1093/ofid/ofac204
work_keys_str_mv AT yetmarzacharya outcomesofbcelldepletedpatientswithcoronavirusdisease2019treatedwithantispikemonoclonalantibodies
AT khodadadiryanb outcomesofbcelldepletedpatientswithcoronavirusdisease2019treatedwithantispikemonoclonalantibodies
AT sevillemariateresa outcomesofbcelldepletedpatientswithcoronavirusdisease2019treatedwithantispikemonoclonalantibodies
AT brumblelisa outcomesofbcelldepletedpatientswithcoronavirusdisease2019treatedwithantispikemonoclonalantibodies
AT ohorojohnc outcomesofbcelldepletedpatientswithcoronavirusdisease2019treatedwithantispikemonoclonalantibodies
AT ganeshravindra outcomesofbcelldepletedpatientswithcoronavirusdisease2019treatedwithantispikemonoclonalantibodies
AT razonableraymundr outcomesofbcelldepletedpatientswithcoronavirusdisease2019treatedwithantispikemonoclonalantibodies

Ejemplares similares